A Novel Approach for Glioblastoma Treatment by Combining Apoptosis Inducers (TMZ, MTX, and Cytarabine) with E.V.A. (Eltanexor, Venetoclax, and A1210477) Inhibiting XPO1, Bcl-2, and Mcl-1

A Novel Approach for Glioblastoma Treatment by Combining Apoptosis Inducers (TMZ, MTX, and Cytarabine) with E.V.A. (Eltanexor, Venetoclax, and A1210477) Inhibiting XPO1, Bcl-2, and Mcl-1

Adjuvant treatment for Glioblastoma Grade 4 with Temozolomide (TMZ) inevitably fails due to therapeutic resistance, necessitating new approaches. Apoptosis induction in GB cells is inefficient, due to an excess of anti-apoptotic XPO1/Bcl-2-family proteins. We assessed TMZ, Methotrexate (MTX), and Cy...

Full description

Bibliographic Details
Main Authors: Kai Zhao, Madita Braun, Leonie Meyer, Katharina Otte, Hartmann Raifer, Frederik Helmprobst, Vincent Möschl, Axel Pagenstecher, Hans Urban, Michael W. Ronellenfitsch, Joachim P. Steinbach, Jelena Pesek, Bernhard Watzer, Wolfgang A. Nockher, R. Verena Taudte, Andreas Neubauer, Christopher Nimsky, Jörg W. Bartsch, Tillmann Rusch
Format: Article
Language:English
Published: MDPI AG 2024-04-01
Series:Cells
Subjects:
glioblastoma
temozolomide
TMZ
methotrexate
MTX
cytarabine
Online Access:https://www.mdpi.com/2073-4409/13/7/632

Internet

https://www.mdpi.com/2073-4409/13/7/632

Similar Items